Terfenadine-Ketoconazole Interaction
- 24 March 1993
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 269 (12), 1513-1518
- https://doi.org/10.1001/jama.1993.03500120051025
Abstract
Objective. —To examine prospectively the effects of ketoconazole on the pharmacokinetics and electrocardiographic repolarization pharmacodynamics (corrected QT intervals) of terfenadine in men and women. Design. —Prospective cohort study with each subject serving as his or her own control. Setting. —Outpatient cardiology clinic and inpatient telemetry unit for monitoring period. Participants. —Six healthy volunteers (four men and two women, aged 24 to 35 years) not taking any prescription or over-the-counter medications. Intervention. —After achieving a steady state while taking terfenadine (60 mg every 12 hours for 7 days), daily concomitant oral ketoconazole (200 mg every 12 hours) was added to the subjects' regimen. Pharmacokinetic profiles were obtained while subjects were taking terfenadine alone and after the addition of ketoconazole. Electrocardiograms were obtained at baseline, after 1 week of taking terfenadine alone, and at the time of the second pharmacokinetic profile after the addition of ketoconazole to the regimen. Main Outcome Measures. —Terfenadine and its acid metabolite serum concentrations and corrected QT intervals. Results. —All subjects had detectable levels of unmetabolized terfenadine after the addition of ketoconazole, which was associated with QT prolongation. Only two of the six subjects could complete the entire course of ketoconazole coadministration. Four subjects received a shortened duration of ketoconazole therapy because of significant electrocardiographic repolarization abnormalities. There was a significant change in the area under the curve of the acid metabolite of terfenadine after the addition of ketoconazole administration. Conclusions. —Ketoconazole alters the metabolism of terfenadine in normal men and women and results in the accumulation of unmetabolized parent drug, which is associated with significant prolongation of the corrected QT interval. This drug combination should be avoided. (JAMA. 1993;269:1513-1518)This publication has 8 references indexed in Scilit:
- AN ANALYSIS OF THE TIME‐RELATIONS OF ELECTROCARDIOGRAMS.Annals of Noninvasive Electrocardiology, 1997
- Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycinClinical Pharmacology & Therapeutics, 1992
- Genetic Aspects of Drug Disposition and TherapeuticsThe Journal of Clinical Pharmacology, 1992
- Determination of terfenadine and terfenadine acid metabolite in plasma using solid-phase extraction and high-performance liquid chromatography with fluorescence detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1991
- QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest.Circulation, 1991
- Block of delayed rectifier potassium current, IK, by terfenadine in cat ventricular myocytesJournal of the American College of Cardiology, 1991
- Erythromycin-induced long QT syndrome: Concordance with quinidine and underlying cellular electrophysiologic mechanismAmerican Journal Of Medicine, 1990
- Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes.JCI Insight, 1983